Amarillo National Bank continued to hold its stake in Johnson & Johnson (NYSE:JNJ) during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,660 shares of the company’s stock at the close of the second quarter. Amarillo National Bank’s holdings in Johnson & Johnson were worth $749,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Trexquant Investment LP purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $1,731,000. State Street Corp raised its holdings in shares of Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after acquiring an additional 6,656,371 shares during the period. DnB Asset Management AS raised its holdings in shares of Johnson & Johnson by 1.2% during the 1st quarter. DnB Asset Management AS now owns 1,305,025 shares of the company’s stock worth $162,541,000 after acquiring an additional 15,600 shares during the period. State of Wisconsin Investment Board raised its holdings in shares of Johnson & Johnson by 8.9% during the 1st quarter. State of Wisconsin Investment Board now owns 2,632,484 shares of the company’s stock worth $327,876,000 after acquiring an additional 216,033 shares during the period. Finally, First National Bank of Omaha raised its holdings in shares of Johnson & Johnson by 8.0% during the 1st quarter. First National Bank of Omaha now owns 52,648 shares of the company’s stock worth $6,558,000 after acquiring an additional 3,919 shares during the period. Institutional investors own 65.90% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) traded up 0.02% during trading on Friday, reaching $133.22. The company’s stock had a trading volume of 2,469,506 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The company has a market capitalization of $357.56 billion, a P/E ratio of 22.54 and a beta of 0.78. The company’s 50-day moving average is $132.23 and its 200-day moving average is $129.87.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period last year, the business posted $1.74 EPS. Equities analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th were issued a $0.84 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/08/amarillo-national-bank-has-749000-holdings-in-johnson-johnson-jnj.html.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Several research analysts have recently commented on JNJ shares. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Royal Bank Of Canada reiterated a “buy” rating and set a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target on the stock. in a report on Friday, July 21st. Jefferies Group LLC reiterated a “hold” rating and set a $145.00 price target (up previously from $140.00) on shares of Johnson & Johnson in a report on Friday, July 14th. Finally, Citigroup Inc. started coverage on Johnson & Johnson in a report on Monday, September 25th. They set a “neutral” rating and a $140.00 price target on the stock. Five research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $134.79.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.